Want to see BEAM full AI Analyst Report?
Beam Therapeutics (BEAM) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Beam-301: Single Dose Of Beam-301 Administered By Iv | Glycogen Storage Disease Type Ia | phase1AndPhase2 | Recruiting | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) | Dec 06, 2024 | ― |
| Beam-302 | Alpha 1-Antitrypsin Deficiency | phase1AndPhase2 | Recruiting | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) | Apr 22, 2024 | ― |
| Beam-201 | Lymphoblastic Lymphoma, Lymphoblastic Leukemia, T-Cell Lymphoblastic Leukemia/Lymphoma | phase1AndPhase2 | Active Not Recruiting | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | May 23, 2023 | ― |
| Beam-101 | Sickle Cell Disease | phase1AndPhase2 | Recruiting | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease | Jun 23, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Beam-301: Single Dose Of Beam-301 Administered By Iv | phase1AndPhase2 | Glycogen Storage Disease Type Ia | Recruiting | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) | Dec 06, 2024 | ― |
| Beam-302 | phase1AndPhase2 | Alpha 1-Antitrypsin Deficiency | Recruiting | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) | Apr 22, 2024 | ― |
| Beam-201 | phase1AndPhase2 | Lymphoblastic Lymphoma, Lymphoblastic Leukemia, T-Cell Lymphoblastic Leukemia/Lymphoma | Active Not Recruiting | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | May 23, 2023 | ― |
| Beam-101 | phase1AndPhase2 | Sickle Cell Disease | Recruiting | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease | Jun 23, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Beam Therapeutics, Inc. (BEAM) have in its pipeline
Beam Therapeutics BEAM is currently developing the following drugs: Beam-301: Single Dose Of Beam-301 Administered By Iv, Beam-302, Beam-201, Beam-101. These drug candidates are in various stages of clinical development as the company works toward FDA approval.